Literature DB >> 11576948

Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients.

S Nakanishi1, J J Kazama, T Shigematsu, Y Iwasaki, T L Cantor, T Kurosawa, M Fukagawa.   

Abstract

Adynamic bone disease has become a major problem in long-term dialysis patients. It has been suggested that higher levels of parathyroid hormone (PTH) are needed to maintain normal bone turnover in uremia. PTH levels currently are evaluated routinely by intact PTH assay, which may detect inactive 7-84 PTH fragments as well as 1-84 PTH. We examined the efficacy of whole PTH assay, which detects 1-84 PTH exclusively, in 99 nondiabetic patients on maintenance dialysis for more than 10 years, without any residual renal function. PTH levels determined by whole PTH assay were lower than those determined by intact PTH assay in all cases. Serum markers of bone metabolism, such as serum activity of bone alkaline phosphatase, correlated well with whole PTH levels. Because 7-84 PTH has been shown to inhibit the effects of 1-84 PTH, the biologic activity of circulating PTH in uremic patients may be much lower than the values assayed by conventional intact PTH assay. Despite an attempt to correlate 1-84 PTH/7-84 PTH ratio with bone histology, we could find only 1 patient out of 99 with 1-84 PTH/7-84 PTH ratio less than 1, which has been suggested to be indicative of low turnover bone. A cutoff value of this ratio should be set in the future for patients with a long hemodialysis history, with various modes of medical therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576948     DOI: 10.1053/ajkd.2001.27436

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 2.  Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients.

Authors:  P D'Amour
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

3.  Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Authors:  Irfana H Soomro; David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

Review 4.  Regulation of parathyroid function in chronic kidney disease (CKD).

Authors:  Masafumi Fukagawa; Shohei Nakanishi; Hideki Fujii; Yasuhiro Hamada; Takaya Abe
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

Review 5.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

6.  Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review.

Authors:  Hirotaka Komaba; Yoko Takeda; Jeongsoo Shin; Reika Tanaka; Takatoshi Kakuta; Yoshihiro Tominaga; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08

7.  The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism.

Authors:  Motoko Tanaka; Hirotaka Komaba; Kazuko Itoh; Kazunori Matsushita; Kazutaka Matshushita; Yasuhiro Hamada; Hideki Fujii; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08

Review 8.  Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective.

Authors:  Manju Chandran; Jiunn Wong
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug

9.  Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Masatomo Taniguchi; Hidehisa Kitada; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Clin Kidney J       Date:  2013-08

10.  Parathyroid hormone assay: problems and opportunities.

Authors:  Kevin J Martin; Esther A González
Journal:  Pediatr Nephrol       Date:  2007-05-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.